Humbi AI by Innovaccer and Landmark Science to Present Real-World Evidence on GLP-1 Use for Cardiometabolic and Cardiovascular Risk Reduction in Medicare Populations at ISPOR 2025

New research highlights demographic, clinical, and access-related insights into GLP-1 and Wegovy use among Medicare beneficiaries.

Montreal, QC, Canada - April 30, 2025-, the leading healthcare AI company, today announced that its recently acquired actuarial science company - Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada.

The research offers new insights into the characteristics of Medicare patients initiating GLP-1 receptor agonists (RAs) and Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction.

The research, leveraging Humbi AI’s high-quality real-world Medicare dataset, provides a timely look into patient populations initiating these therapies—an area of growing importance as GLP-1 RAs expand beyond diabetes management.

“The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity,” said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. “At ISPOR, we’re excited to share data that helps stakeholders better understand who is initiating these therapies - and who might be left behind.”

“The importance of real-world evidence in understanding semaglutide’s impact on cardiovascular disease among Medicare patients cannot be overstated, particularly given the risk of heart attack and stroke among this older population,” said Shivani Aggarwal - CEO of Landmark Science.

The two joint poster presentations by HumbiAI and Landmark Science, Inc. include:

• Poster #EPH74 (Poster Session 2, 14th May, 4:00PM - 7:00PM): 
  Characteristics of Patients Initiating Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population 
  This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. 
  
  View Poster Abstract 

• Poster #EPH113 (Poster Session 3, 15th May, 10:30AM - 1:30PM): 
  Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population 
  Focused specifically on Wegovy, this analysis offers a more granular view into prescribing trends, demographic disparities, and outcomes among older adults at high cardiovascular risk. 
  
  View Poster Abstract

To learn how Humbi AI by Innovaccer can support your organization with actionable real-world insights and evidence generation - Read More.

About Humbi AI by Innovaccer

Humbi AI by Innovaccer is an actuarial intelligence company powered by Medicare, Medicaid, and Commercial datasets enabling providers, payers, and life sciences organizations to manage risk, improve performance, and succeed in value-based care. With deep actuarial expertise, robust benchmarking data, and flexible financial modeling software, Humbi AI provides powerful analytics and consultative services that transform complex challenges into actionable insights. By simplifying risk management and enhancing decision-making, Humbi AI by Innovaccer helps organizations drive better outcomes and sustainable growth. For more information, visit humbi.ai.